Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Covance, a provider of drug development services, has purchased a minority equity stake in Caprion Proteomics, a provider of proteomics-based services to the pharmaceutical industry, to further enhance its biomarker service offerings to clients.
Subscribe to our email newsletter
Pursuant to terms of the agreement, Covance will serve as the exclusive contract research organization distributor of Caprion’s proteomic biomarker services. In addition, Caprion will serve as Covance’s exclusive proteomic discovery provider. Through this alliance, Covance and Caprion will offer pharmaceutical and biotechnology drug development customers a distinctive, innovative, and integrated biomarker solution.
To further accelerate and support the growth of its biomarker business, Covance plans to establish a Biomarker Center of Excellence at its campus in Greenfield, Indiana. Leading Covance’s biomarker business will be Thomas Turi, Covance’s new vice president of biomarkers.
In his new role, Dr Turi will be responsible for building Covance’s Center of Excellence for Biomarkers in Greenfield and leading Covance’s biomarker expert team, a panel of top scientists representing Covance’s biomarker capabilities.
Deborah Tanner, president of central laboratory services at Covance, said: “We are very pleased to be adding Caprion’s solid scientific capabilities and leading biomarker technology platform to Covance’s line up. We expect that our clients will have a keen interest in this additional capability given Caprion’s impressive track record of accelerating biomarker validation for early drug safety and efficacy assessment.”